X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/007158.html
https://www.raps.org/news-and-articles/news-articles/2020/6/ema-recommends-eight-new-medicines-refuses-one
http://www.pharmafile.com/news/525725/daiichi-sankyos-turalio-becomes-first-fda-approved-therapy-rare-tumour
https://endpts.com/daiichi-sankyo-scores-fda-ok-for-rare-tumor-drug-albeit-with-restrictions/
https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-rare-joint-tumor
https://www.prnewswire.com/news-releases/fda-approves-daiichi-sankyos-turalio-pexidartinib-for-the-treatment-of-select-patients-with-tgct-a-rare-and-debilitating-tumor-300895924.html
https://www.prnewswire.com/news-releases/fda-approves-first-therapy-for-rare-joint-tumor-300895801.html
https://www.prnewswire.com/news-releases/daiichi-sankyos-pexidartinib-demonstrated-further-improvement-with-continued-treatment-of-tenosynovial-giant-cell-tumor-patients-in-new-long-term-analysis-presented-at-2019-asco-annual-meeting-300860162.html
https://www.prnewswire.com/news-releases/fda-oncologic-drugs-advisory-committee-votes-in-favor-of-daiichi-sankyos-pexidartinib-for-the-treatment-of-select-patients-with-tgct-a-rare-debilitating-tumor-300849939.html
Market Place
Share 
